BeOne Medicines reports positive results from phase 3 MANGROVE study of Brukinsa in frontline mantle cell lymphoma: San Carlos, California Thursday, July 2, 2026, 10:00 Hrs [IST] ...

Independent review–assessed PFS met the primary endpoint with zanubrutinib-rituximab versus bendamustine-rituximab (HR, 0.57; P<.0001), supporting a chemotherapy-free frontline strategy in MCL.

Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...

A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...

Gazyva is a prescription injection medicine used for people with certain cancers, such as chronic lymphocytic leukemia (CLL) and certain types of follicular lymphoma. It is a type of medicine known as ...

There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma that affects white blood cells called ...

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of blood cancer that that develops from B cell precursors. Healthy B cells produce a broad range of infection-fighting antibodies, making them ...

Rituximab, sometimes used off-label as a multiple sclerosis (MS) treatment, may be as effective — at a much lower cost to patients — as the approved therapy Ocrevus (ocrelizumab) at managing relapsing ...

No patients with pemphigus who had predictors of early relapse and received additional treatment with rituximab experienced relapse at 12 months. A personalized treatment strategy among patients with ...